Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 3
- Registration Number
- NCT00665444
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2021-02-21
- Target Recruit Count
- 256
- Registration Number
- NCT00634348
- Locations
- 🇺🇸
Pfizer Investigational Site, Falls Church, Virginia, United States
Study of Aripiprazole to Treat Children and Adolescents With Autism
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 30
- Registration Number
- NCT00619190
- Locations
- 🇺🇸
University of North Carolina, Department of Psychiatry, Chapel Hill, North Carolina, United States
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT00608543
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT00606229
A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 59
- Registration Number
- NCT00606320
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 258
- Registration Number
- NCT00606281
A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT00606177
Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00592683
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 164
- Registration Number
- NCT00580125
- Locations
- 🇺🇦
Pfizer Investigational Site, Lugansk, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.